Why GLP-1 Drugs Alone Aren’t Enough for Lasting Weight Loss
In a recent conversation with Managed Healthcare Executive, Geoffrey Rutledge, M.D., of HealthTap, warned that the narrative around GLP-1 drugs is often oversimplified—and potentially harmful.
Geoffrey Rutledge, M.D., chief medical officer at HealthTap, wants patients to rethink how they approach GLP-1 medications like Ozempic and Wegovy (both versions of semaglutide), as these obesity and some type 2 diabetes drugs have rapidly gained popularity for their role in weight loss.
In a recent conversation with Managed Healthcare Executive, Rutledge warned that the narrative around these drugs is often oversimplified—and potentially harmful.
“Probably the biggest thing people need to recognize is that it’s a journey,” Rutledge said. “It’s not, as you say, a quick fix that happens right away.”
GLP-1 drugs work by suppressing appetite, leading to reduced calorie intake over time. But the effects don’t last without continued use or significant lifestyle changes, he said.
“As soon as you stop the medicine, all of the previous appetite comes back,” he explained.
Even those who lose 15% to 20% of their body weight may regain it if they don’t make lasting behavioral changes.
“When you lose weight, you’re losing both muscle and fat. When you gain it back quickly, you tend to gain back the fat,” he added.
The promise of GLP-1s is real, but only when patients use them with a long-term plan. Rutledge emphasized the importance of building healthier routines around eating, exercise and stress management.
“There is a path to keep the weight off,” he said, “but it involves recognizing that you need to modify your lifestyle, develop healthy eating habits, and more important, develop a lifestyle that includes exercise and management of the stress or the other issues in your life that may be encouraging you to eat more.”
As telehealth platforms increasingly offer GLP-1 prescriptions, Rutledge also stressed that quick online consults aren’t enough.
“The challenge of telehealth is that people expect a quick visit to get the prescription, and that’s all they have to do,” he says.
But when done right, virtual care can mirror in-person programs.
“Participating with the program is the key element,” he said. “The telehealth companies that are doing that well engage their patients in those lifestyle changes, creating a relationship and ongoing care, which is really essential.”
While cost remains a concern—especially in the U.S., where retail prices hover around $1,000 a month—Rutledge believes broader access and affordability are on the horizon as more options enter the market.
Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Survey: What Patients and Providers Are Thinking About Healthcare Access
April 28th 2025Patients and providers found common ground on the importance of correct billing estimates but did not see eye to eye in terms of digital scheduling tool use, according to a new survey by Experian Health.
Read More
